DOP2020000082A - Administración oral de análogos del péptido glp-1 - Google Patents

Administración oral de análogos del péptido glp-1

Info

Publication number
DOP2020000082A
DOP2020000082A DO2020000082A DO2020000082A DOP2020000082A DO P2020000082 A DOP2020000082 A DO P2020000082A DO 2020000082 A DO2020000082 A DO 2020000082A DO 2020000082 A DO2020000082 A DO 2020000082A DO P2020000082 A DOP2020000082 A DO P2020000082A
Authority
DO
Dominican Republic
Prior art keywords
glp
oral administration
peptide analogues
formulations
methods
Prior art date
Application number
DO2020000082A
Other languages
English (en)
Inventor
Tyagi Puneet
Anand Subramony Janardhanan
Pechenov Sergei
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of DOP2020000082A publication Critical patent/DOP2020000082A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona formulaciones para administración oral de análogos del péptido GLP-1, métodos para preparar tales formulaciones, y métodos de tratamiento que usan tales formulaciones.
DO2020000082A 2017-10-31 2020-05-06 Administración oral de análogos del péptido glp-1 DOP2020000082A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762579186P 2017-10-31 2017-10-31
PCT/IB2018/058514 WO2019087083A2 (en) 2017-10-31 2018-10-30 Oral delivery of glp-1 peptide analogs

Publications (1)

Publication Number Publication Date
DOP2020000082A true DOP2020000082A (es) 2020-08-31

Family

ID=66331379

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2020000082A DOP2020000082A (es) 2017-10-31 2020-05-06 Administración oral de análogos del péptido glp-1

Country Status (23)

Country Link
US (1) US11173124B2 (es)
EP (1) EP3703817A4 (es)
JP (1) JP2021501172A (es)
KR (1) KR20200081411A (es)
CN (1) CN111655338A (es)
AR (1) AR116451A1 (es)
AU (1) AU2018360382A1 (es)
BR (1) BR112020008220A2 (es)
CA (1) CA3079376A1 (es)
CL (1) CL2020001131A1 (es)
CO (1) CO2020005485A2 (es)
CR (1) CR20200185A (es)
DO (1) DOP2020000082A (es)
EA (1) EA202091095A1 (es)
IL (1) IL274096A (es)
MA (1) MA50047A (es)
MX (1) MX2020004497A (es)
PE (1) PE20210116A1 (es)
PH (1) PH12020551018A1 (es)
SG (1) SG11202003627PA (es)
TW (1) TW201932139A (es)
WO (1) WO2019087083A2 (es)
ZA (1) ZA202003149B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA50047A (fr) 2017-10-31 2020-07-08 Medimmune Ltd Administration orale d'analogues peptidiques de glp-1
CN116940384A (zh) * 2020-11-27 2023-10-24 D&D制药技术股份有限公司 具有与生物素部分、脂肪酸部分或其组合偶联的生物活性材料缀合物的口服制剂
FR3120189B1 (fr) 2021-03-01 2024-11-29 Farid Bennis Composition pharmaceutique pour une administration par voie orale d’un agoniste du récepteur du GLP-1
KR20230010571A (ko) 2021-07-12 2023-01-19 한미약품 주식회사 Glp-1 유사체를 함유하는 경구 투여 제형 조성물
WO2023065231A1 (en) * 2021-10-21 2023-04-27 Guangzhou Dazhou Biomedicine Ltd. Oral delivery of therapeutic agents
WO2023161792A1 (en) * 2022-02-22 2023-08-31 Astrazeneca Ab Compressible sodium caprate formulations
US12605427B2 (en) * 2023-05-15 2026-04-21 Red Mountain Med Spa, LLC Sublingual semaglutide-BPC 157 combination for weight loss
WO2026085450A1 (en) * 2024-10-18 2026-04-23 Primary-9 Llc Pharmaceutical compositions for direct systemic introduction

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556837A (en) * 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
GB0308734D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
EP2679270B1 (en) 2011-02-24 2016-11-09 Hisamitsu Pharmaceutical Co., Inc. Glp-1 analogue composition for microneedle devices
WO2013148966A1 (en) * 2012-03-28 2013-10-03 Amylin Pharmaceuticals, Llc Transmucosal delivery of engineered polypeptides
RS58039B1 (sr) * 2013-05-02 2019-02-28 Novo Nordisk As Oralno doziranje glp-1 jedinjenja
EP3003267A1 (en) 2013-05-30 2016-04-13 Novo Nordisk A/S Novel oral pharmaceutical composition for treatment of diabetes
TWI726889B (zh) * 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
CN106366166A (zh) * 2016-08-30 2017-02-01 苏州普罗达生物科技有限公司 脑源性神经营养因子促进剂多肽及应用
MA50047A (fr) 2017-10-31 2020-07-08 Medimmune Ltd Administration orale d'analogues peptidiques de glp-1

Also Published As

Publication number Publication date
EA202091095A1 (ru) 2020-09-18
MX2020004497A (es) 2020-08-13
EP3703817A2 (en) 2020-09-09
CO2020005485A2 (es) 2020-05-15
CA3079376A1 (en) 2019-05-09
IL274096A (en) 2020-06-30
PE20210116A1 (es) 2021-01-19
MA50047A (fr) 2020-07-08
US11173124B2 (en) 2021-11-16
WO2019087083A3 (en) 2019-08-08
AR116451A1 (es) 2021-05-12
EP3703817A4 (en) 2021-08-18
CR20200185A (es) 2020-06-19
WO2019087083A2 (en) 2019-05-09
AU2018360382A1 (en) 2020-06-18
CL2020001131A1 (es) 2020-10-23
KR20200081411A (ko) 2020-07-07
CN111655338A (zh) 2020-09-11
BR112020008220A2 (pt) 2020-10-27
US20200323782A1 (en) 2020-10-15
PH12020551018A1 (en) 2021-05-31
ZA202003149B (en) 2021-06-30
TW201932139A (zh) 2019-08-16
JP2021501172A (ja) 2021-01-14
SG11202003627PA (en) 2020-05-28

Similar Documents

Publication Publication Date Title
CO2020005485A2 (es) Administración oral de análogos del péptido glp-1
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
CL2020000422A1 (es) Composiciones de glp-1 y sus usos.
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
MX392572B (es) Compuestos del péptido yy (pyy) selectivos y sus usos.
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
MX2016016533A (es) Combinaciones inmunogenas.
MX2016010854A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de un antagonista de il-4r.
MX2017014532A (es) Vacunas para el tratamiento y prevencion del cancer.
CY1124761T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
MX2013002207A (es) Vacunas contra el cancer cerebral basadas en peptido alfa 2 del receptor de interleucina 13.
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
MX2016014826A (es) Conjugados de peptido-curcumina y formulaciones de los mismos.
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
BR112017009510A2 (pt) composições compreendendo ciclosporina
MX2016011535A (es) Ureas asimetricas p-sustituidas y usos medicos de las mismas.
BR112017009358A2 (pt) imunoterapia específica de peptídeo t terapêutico para uso no tratamento de metástase cerebral de um paciente com hla-2 positivo
WO2016172269A3 (en) Insulin analogs having shortened b chain peptides and associated methods
MX2017006513A (es) Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor.
CO2018004803A2 (es) Compuestos oxa-diazaspiro que tienen actividad contra el dolor
CL2021003497A1 (es) Composiciones farmacéuticas para péptidos co-agonistas de glucagón y glp-1
MX2018003289A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA AUMENTAR LA RECUPERACION DE TRAUMA DE TEJIDO BLANDO.
MX2021016053A (es) Formulaciones de espuma rectal.
EA201892095A1 (ru) Циклические динуклеотидные соединения и способы их применения